IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0894786
(2004-07-20)
|
등록번호 |
US-8313775
(2012-11-20)
|
발명자
/ 주소 |
- Burnside, Beth A.
- Flanner, Henry H.
- Rowlings, Colin
|
출원인 / 주소 |
|
대리인 / 주소 |
MH2 Technology Law Group LLP
|
인용정보 |
피인용 횟수 :
0 인용 특허 :
266 |
초록
▼
An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a sustained release dosage form, an
An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a sustained release dosage form, and a delayed release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
대표청구항
▼
1. A once-a-day antibiotic product comprising: first, second, and third antibiotic dosage forms, each of said antibiotic dosage forms comprising at least one antibiotic and a pharmaceutically acceptable carrier, said first antibiotic dosage form being an immediate release dosage form, said second an
1. A once-a-day antibiotic product comprising: first, second, and third antibiotic dosage forms, each of said antibiotic dosage forms comprising at least one antibiotic and a pharmaceutically acceptable carrier, said first antibiotic dosage form being an immediate release dosage form, said second antibiotic dosage form being a sustained release dosage form, and said third antibiotic dosage form being a delayed release dosage form, wherein said second dosage form initiates release of antibiotic at about the same time as said first dosage form initiates release of antibiotic or wherein said second dosage form initiates release of antibiotic after said first dosage form initiates release of antibiotic, and wherein said third dosage form initiates release of antibiotic after said second dosage form initiates release of antibiotic, and Cmax of the total antibiotic released from said antibiotic product is achieved in less than about 12 hours from administration and said once-a-day antibiotic product contains the total dosage of the at least one antibiotic for a twenty-four hour period, wherein said once-a-day antibiotic product does not contain any additional dosage forms; wherein the antibiotic product is an oral dosage form; wherein the antibiotic released from the first dosage form reaches a Cmax within from about 0.5 hours to about 2 hours after administration of the product; wherein the antibiotic released from the second dosage form reaches a Cmax after Cmax is reached for the antibiotic released from the first dosage form and wherein the first dosage form contains about 20-70% of the total dosage of antibiotic, the second dosage form contains about 10-70% of the total dosage of antibiotic, and the third dosage form contains about 10-70% of the total dosage of antibiotic. 2. The product of claim 1, wherein said second dosage form initiates release of antibiotic at about the same time as said first dosage form initiates release of antibiotic. 3. The product of claim 1, wherein said second dosage form initiates release of antibiotic after said first dosage form initiates release of antibiotic. 4. The product of claim 1, wherein the Cmax for the product is reached no earlier than four hours after administration. 5. The product of claim 1, wherein the antibiotic released from the third dosage form reaches a Cmax after Cmax is reached for the antibiotic released from the second dosage form. 6. The product of claim 1, wherein the first dosage form contains about 25-66% of the total dosage of antibiotic, the second dosage form contains about 15-60% of the total dosage of antibiotic, and the third dosage form contains about 15-60% of the total dosage of antibiotic. 7. The product of claim 1, wherein the first dosage form contains about 33-60% of the total dosage of antibiotic, the second dosage form contains about 25-50% of the total dosage of antibiotic, and the third dosage form contains about 25-50% of the total dosage of antibiotic. 8. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 1, once-a-day. 9. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 2, once-a-day. 10. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 3, once-a-day. 11. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 4, once-a-day. 12. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 5, once-a-day. 13. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 6, once-a-day. 14. A process for treating a bacterial infection in a host comprising: administering to a host the antibiotic product of claim 7, once-a-day. 15. The product of claim 1, wherein said at least one antibiotic is amoxicillin. 16. The product of claim 1, wherein said at least one antibiotic is cephalexin.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.